Antitumor activity of irinotecan with ellagic acid in C6 glioma cells
Abdurrahman Cetin1*, Burcu Biltekin2, Huseyin Ozevren3

INTRODUCTION
Malignant glioma is one of the common primary brain tumors detected in the adults. These lesions, highly malignant, easily and diffusely infiltrate the tissues, so that the optimal therapy against these tumors is the combination of surgical resection, radiation therapy, and chemotherapy1,2.

The successful treatment options are limited for the recurrent gliomas, and progression-free survival is measured as approximately 10 weeks and overall survival as 30 weeks3. Therefore, new therapeutic strategies using the combinations of effective compounds with essential chemotherapeutic are essentially required to improve the success of treatments by preventing recurrence and to promote the quality of life of glioma patients4.

Irinotecan (Ir), an inhibitor of the topoisomerase I enzyme, has a high anticancer effect on the solid tumors in the gastrointestinal tract. This drug, which easily cross the blood-brain barrier, has been proven cytotoxic and antitumor activity of the brain tumors, such as glial neoplasms with multidrug resistance, in preclinical studies5,6. Although research has proved the monotherapy of the Ir as efficient, its activity does not have combined effect with other agents7. Its combination with other chemotherapeutic agents in the malignant gliomas needs further study1,7.

Ellagic acid (EA) is a natural polyphenolic compound derived from ellagitannins found in foods with reported antioxidant, anti-inflammatory, and antifibrotic properties8,9. However, the potential synergistic effect of Ir with EA, i.e., a common chemotherapeutic agent, is poorly understood for the treatment of gliomas.

The epithelial-to-mesenchymal transition (EMT) provides an aggressive behavior of the tumor cells by reducing the expression or loss of epithelial markers such as adherent junction proteins α-catenin, β-catenin, E-cadherin and by increasing the expression of mesenchymal markers such as vimentin and N-cadherin10,11.

Glial neoplasms are a highly vascular cancer and also rich in the expression of vascular endothelial growth factor (VEGF) that promotes the process of angiogenesis. Antiangiogenic agents may prevent this process and promote regression of existing vessels12.

We aimed to demonstrate the antitumor effects of the treatment of Ir with EA in C6 glioma cell line.
METHODS

Cell culture
C6 glioma cells were purchased from the American Type Culture Collection (Manassas, VA, USA), and all procedures were in accordance with steps described in previous studies.13,14

Immunocytochemistry
To determine the immunoreactivities of E-cadherin, N-cadherin, and VEGF, all steps of immunocytochemistry (ICC) and H-SCORE analysis described in previous studies were applied in this study.13,14

Expression analysis
The expression levels of E-cadherin, N-cadherin, and VEGF were determined following all steps of real-time quantitative polymerase chain reaction (qPCR) described in our previous studies.13,14

5-Bromo-2′-deoxyuridine cell proliferation assay
5-Bromo-2′-deoxyuridine (Br-dU) ICC was used to examine the cell proliferation, and all procedures and scoring were in accordance with steps described in our previous studies.13,14

Statistical analysis
Semi-quantitative and quantitative data from all groups were statistically analyzed by using GraphPad InStat version 3.06 (GraphPad Software, San Diego, CA, USA). All data were represented as mean±SD. The means of continuous variables were calculated using a one-way analysis of variance, and variations between the groups were compared using a post-hoc Tukey’s multiple comparison test. A p-value <0.05 was accepted as statistically significant.

RESULTS

Combined Ellagic acid and Irinotecan suppresses the cell proliferation
To define the efficacy of Ir with or without EA on the cell proliferation of C6 glioma, the Br-dU proliferation assay was performed, and the scores were semi-quantitatively analyzed. Irinotecan treatment alone significantly inhibits the cell proliferation at the 24th (control: 84.87±2.25; Ir: 47.22±1.91, p<0.001), 48th (control: 88.48±2.37; Ir: 47.25±2.63, p<0.001), and 72nd (control: 86.10±1.65; Ir+EA: 35.98±2.24, p<0.001) hours of incubations. In contrast, the combination with EA inhibited the proliferation more distinctly compared to the control group at 24th (control: 84.87±2.25, Ir+EA: 5.01±0.52, p<0.001), 48th (control: 88.48±2.37; Ir+EA: 8.45±0.99, p<0.001), and 72nd (control: 86.10±1.65; Ir+EA: 1.52±0.63, p<0.001) hours of incubations.

Combined Ellagic acid and Irinotecan mediates the cadherin switch at the gene and protein levels
The expressions of E-cadherin and N-cadherin were quantified by qPCR. Their protein levels were studied by ICC, as shown in Figures 1 and 2. Treatment with only Ir considerably upregulated the protein levels of E-cadherin expression at all incubation hours in cells compared to the control group at 24th (control: 10; Ir: 45), 48th (control: 8; Ir: 30), and 72nd (control: 5; Ir: 25) hours of incubation (p<0.01) (Figure 1). However, the gene level of E-cadherin was only significantly higher than the control group at 24th incubation time (control: 1.0; Ir: 1.6, p<0.05). In contrast, Ir treatment with EA dramatically increased E-cadherin expression at 24th (control: 1.0; Ir+EA: 3.3, p<0.001), 48th (control: 1.0; Ir+EA: 2.0, p<0.01), and 72nd (control: 1.0; Ir+EA: 1.8, p<0.05) hours of incubation, and protein levels significantly increased at 24th (control: 10; Ir+EA: 80), 48th (control: 8; Ir+EA: 55), and 72nd (control: 5; Ir+EA: 45) (p<0.001) hours of incubation (Figure 1).

The treatment of Ir without EA reduced N-cadherin gene levels significantly at 24th hour (control: 7.6; Ir: 4.8, p<0.01), but failed to reduce gene levels at 48th (control: 5.1; Ir: 4.0, p>0.05) and 72nd (control: 5.0; Ir: 3.2, p>0.05) hours of incubation, compared to the control group. Irinotecan without EA significantly reduced the N-cadherin protein level at 24th hour (control: 120; Ir: 55) (p<0.01), but failed to reduce at 48th and 72nd hours of incubation (p>0.05) (Figure 2), as well as Ir with EA significantly decreased the gene levels all the time at 24th (control: 7.6; Ir+EA: 3.0, p<0.001), 48th (control: 5.1; Ir+EA: 2.8, p<0.05), and 72nd (control: 5.0, Ir+EA: 1.9, p<0.01). Irinotecan with EA reduced the protein levels of N-cadherin at 24th (control: 120; Ir+EA: 30, p<0.001) and 72nd (control: 62; Ir+EA: 20, p<0.01) hours of incubation (Figure 2).

Combined Ellagic acid and Irinotecan downregulates the expression of VEGF at the gene and protein levels
The treatment of Ir without EA significantly downregulated the gene levels of VEGF expression at 24th (control: 2.0; Ir: 1.3, p<0.01) hour of incubation compared with the control group, and Ir treatment with EA dramatically downregulated the gene levels of VEGF expression at 24th (control: 2.0; Ir+EA: 1.0, p<0.001), 48th (control: 2.5; Ir+EA: 0.9, p<0.001), and 72nd (control: 1.5; Ir+EA: 0.5, p<0.001) hours. In contrast, Ir
Figure 1. Immunocytoactivity of E-cadherin in the control (C). EA: ellagic acid; Ir: irinotecan. Combination (ellagic acid+irinotecan) groups, compared with the time of exposure. Magnification: ×400.

Figure 2. Immunocytoactivity of N-cadherin in the control (C). EA: ellagic acid; Ir: irinotecan. Combination (ellagic acid+irinotecan) groups, compared with the time of exposure. Magnification: ×400.
without EA significantly decreased the protein levels of VEGF at 48th (control: 42; Ir: 25, p<0.01) and 72nd (control: 22; Ir: 12, p<0.05) hours of incubation, and Ir with EA decreased significantly at 24th (control: 34; Ir+EA: 6), 48th (control: 42; Ir+EA: 5), and 72nd (control: 22; Ir+EA: 4) hours at all incubation times (p<0.001) (Figure 3).

DISCUSSION
There are several modern therapies against glioma cells; however, it is still a fatal malignant disease with extremely poor prognosis1,2. Irinotecan, a topoisomerase I inhibitor, has been a new option6. The active metabolite of Ir is 7-ethyl-10-hydroxycamptothecin (SN-38), produced by the breakdown of the Ir catalyzed by carboxylesterase enzyme15. Irinotecan can be directly converted to SN-38 in glioma cells, resulting in an increase in SN-38 level, a decrease in proliferation, increase in the apoptosis, and induction of morphological changes16,17. Coggins et al.7 demonstrated that Ir was effective in animal models of a variety of CNS tumor xenografts. Nakatsu et al.16 revealed the antitumor activity of Ir, i.e., multidrug resistance, in human GBM cells. In combination with Ir, the progressive nature and poor prognosis of disease in patients with malignant primary brain tumors compelled the scientists to investigate an alternative agent with novel potent action. Irinotecan, applied as either a monotherapy or a combined therapy with other agents, has been largely studied to treat these malignant and fatal gliomas15,18.

These combination therapies with Ir targeting the cadherin switch during EMT have been more beneficial than the conventional mono-chemotherapy regimens used against malignant, persistent, or resistant gliomas16,17. EMT represents the process in which cells undergo phenotypic changes by losing the cell polarity and cell-cell junctions. EMT results in a transformation from the unipolar and immobile cells into the mobile mesenchymal cells. This transformation of cells plays a fundamental role in the invasion and metastasis of a variety of cancers10,11. E-cadherin and N-cadherin are essential players of EMT process in the mechanisms of invasion and metastasis of tumors, resulting in the therapeutic resistance of gliomas. This study showed that the synergistic effects of EA treatment with Ir via altering the expression of E-cadherin and N-cadherin, as well as the expression of VEGF in a model of C6 glioma cells. The combination treatment of the EA with Ir selectively elevated
E-cadherin expression while decreasing N-cadherin expression in a time-independent manner, suggesting a modulatory effect on EMT pathways in GBM cells. Moreover, the treatment EA with Ir decreased the expression of VEGF, regardless of incubation time, suggesting an antiangiogenic effect in glioma cells.

Noronha et al.\textsuperscript{10} reported the E-cadherin and N-cadherin in gliomas and suggested that EMT process is compromised by increased N-cadherin expression, causing a poor prognosis, and resistance to the cancer therapies in the patients with glioma. In this study, the EA application with or without Ir considerably reversed the cadherin switch by upregulating E-cadherin expression and downregulating N-cadherin, offering an antitumor activity of EA via interfering with the EMT process in C6 glioma cells.

Angiogenesis plays an essential function in the tumor progression; however, it function is provoked by the altered levels of several proangiogenic factors including VEGF and by the abnormal hypoxic microenvironment of gliomas\textsuperscript{19,20}. Therapeutic agents have been developed in combination therapies in order to inhibit this angiogenesis process mostly by targeting the members of the VEGF family, resulting in a decrease in the incidence of gliomas and resultant mortality\textsuperscript{14}. Some studies have proposed that EA could inhibit angiogenesis in cancer by decreasing the number of blood vessels\textsuperscript{13}. Hosny et al.\textsuperscript{21} showed that EA has a significant antiproliferative effect on the in vivo behavior in cancer animal models.

Kamiyama et al.\textsuperscript{22} reported that under normoxic and hypoxic conditions, Ir considerably downregulated the expression of VEGF in glioma cells in a time- and dose-dependent manner. Irinotecan has been suggested to inhibit both the endothelial proliferation and vessel formation and the angiogenic pathways in glioma cells. Additionally, the EMT process is predominantly induced by a hypoxia in the microenvironment and the microvascular proliferation via the expression of VEGF in glioma cells\textsuperscript{10,22}. This study also supported these in vitro effects of EA on VEGF expression when combined with Ir, indicating the downregulation of its expression and reduction of its immunoreactivity. Therefore, findings showed that the antitumor activity of Ir with EA enhanced the promoting antiangiogenic processes in glioma cells.

**CONCLUSION**

An in vitro antitumor activity of Ir was exerted by combining with EA in C6 glioma cells. Moreover, in vitro and clinical studies are needed to clarify whether a combined strategy leads to a higher efficacy in the treatment of aggressive cancers than do a chemotherapeutic monotherapy alone, and whether these combinations could reduce the dose of agents and minimize the side effects of cytotoxic therapies.

**AUTHORS’ CONTRIBUTIONS**

AC: Conceptualization, data curation, formal analysis, writing – original draft, Writing – review & editing. BB: Conceptualization, data curation, formal analysis, writing – original draft, Writing – review & editing. HO: Conceptualization, data curation, formal analysis, writing – original draft, writing – review & editing.

**REFERENCES**

1. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, et al. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018;24(2):295-305. https://doi.org/10.1158/1078-0432.CCR-17-0963
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. https://doi.org/10.1056/NEJMoa043330
3. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11(1):80-91. https://doi.org/10.1215/15228517-2008-075
4. Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A. 2015;112(3):851-6. https://doi.org/10.1073/pnas.1320611111
5. Lo HW. EGFR-targeted therapy in malignant gliomas: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2010;3(1):37-52. https://doi.org/10.2174/1874467211003010037
6. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 1994;20(1):73-96. https://doi.org/10.1016/0305-7372(94)90011-6
7. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998;41(6):485-90. https://doi.org/10.1007/s002800050771
8. Narayan BA, Geoffroy Q, Willingham MC, Re GG, Nixon DW, p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999;136(2):215-21. https://doi.org/10.1016/s0304-3835(98)00323-1
9. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicaglin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005;16(6):360-7. https://doi.org/10.1016/j.jnutbio.2005.01.006
10. Noronha C, Ribeiro AS, Taipa R, Castro DS, Reis J, Faria C, et al. Cadherin Expression and EMT: A Focus on Gliomas. Biomedicines. 2021;9(10):1328. https://doi.org/10.3390/biomedicines9101328
11. Noh MG, Oh SJ, Ahn EJ, Kim YJ, Jung TY, Jung S, et al. Prognostic significance of E-cadherin and N-cadherin expression in Gliomas. BMC Cancer. 2017;17(1):583. https://doi.org/10.1186/s12885-017-3591-z

12. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-9. https://doi.org/10.1200/JCO.2007.12.2440

13. Çetin A, Biltekin B. Ellagic Acid enhances antitumor efficacy of temozolomide in an in vitro glioblastoma model. Turk Neurosurg. 2020;30(6):813-21. https://doi.org/10.5137/1019-5149.JTN.26026-19.1

14. Çetin A, Biltekin B, Degirmencioglu S. Ellagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model. World Neurosurg. 2019;132:e59-e65. https://doi.org/10.1016/j.wneu.2019.08.257

15. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos. 1997;25(10):1157-64. PMID: 9321519

16. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997;39(5):417-23. https://doi.org/10.1007/s002800050592

17. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13(12):1841-51. https://doi.org/10.1093/annonc/mdf337

18. Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004;6(1):21-7. https://doi.org/10.1215/s1152851703000218

19. Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. FEBS J. 2009;276(17):4636-43. https://doi.org/10.1111/j.1742-4658.2009.07175.x

20. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190-200. https://doi.org/10.1172/JCI70212

21. Hosny KM, Rizg WY, Khallaf RA. Preparation and optimization of in situ gel loaded with rosuvastatin-ellagic acid nanotransfersomes to enhance the anti-proliferative activity. pharmaceutics. 2020;12(3):263. https://doi.org/10.3390/pharmaceutics12030263

22. Kamiyama H, Takano S, Tsuibo K, Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol. 2005;131(4):205-13. https://doi.org/10.1007/s00432-004-0642-z